Epacadostat
- Generic Name
- Epacadostat
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 1
Completed
- Conditions
- Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02166905
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 2
- Registration Number
- NCT02118285
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Early Phase 1
Completed
- Conditions
- Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIA Ovarian Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT02042430
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Phase 2
Completed
- Conditions
- Stage IIIC Uveal MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin MelanomaRecurrent MelanomaStage IV Uveal MelanomaMucosal MelanomaRecurrent Uveal MelanomaStage IIIA Uveal Melanoma
- Interventions
- Biological: MELITAC 12.1 Peptide Vaccine
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01961115
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2016-01-18
- Target Recruit Count
- 15
- Registration Number
- NCT01822691
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Phase 2
Terminated
- Conditions
- Genitourinary (GU) TumorsOvarian Cancer
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT01685255
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01604889
A Dose-escalation Study in Subjects With Advanced Malignancies
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 52
- Registration Number
- NCT01195311
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath